ArticleJAC-antimicrobial resistance2025
Combatting mobile colistin-resistant (MCR), metallo-β-lactamase (MBL)-producing
Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Resensitizing the Untreatable: Zidovudine and Polymyxin Combinations to Combat Pan-Drug-ResistantPharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Objectives: Therapeutic modalities for pan-drug-resistant Gram-negatives co-expressing mobile colistin resistance and metallo-β-lactamases have not been defined. Here, we devised novel strategies involving aztreonam and ceftazidime/avibactam together with polymyxin B to combat persisters of a pan-drug-resistant Methods: A hollow fibre infection model was utilized to profile the clinical combination of aztreonam + ceftazidime/avibactam + polymyxin B against a pan-drug-resistant Results: The clinical combination of aztreonam + ceftazidime/avibactam demonstrated initial activity with a total count reduction of 2.69 log Conclusions: Despite intrinsic
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.